Thu Sep 29, 2011 9:11am EDT
Reuters
* Reuters is not responsible for the content in this press release.
New proton beam therapy center in the City of London to install ProTom’s Radiance 330TM proton therapy system
ProTom International, Inc. (“ProTom”) is proud to announce it has entered into an arrangement with United Kingdom-based Advanced Proton Solutions Holdings Limited (“APS”) to provide its Radiance 330 proton therapy system for the new APS facility that will be built in the City of London.
“Advanced Proton Solutions represents an ideal partner for ProTom’s first international venture. Due to its modular design and smaller footprint, our Radiance 330 system is a great solution for sustainable urban locations such as the City of London,” said Stephen Spotts, CEO of ProTom.
“Proton beam therapy represents an innovation in cancer treatment, and ProTom’s technology will allow the development of the APS purpose-built facility in Moorgate, City of London. APS is proud to take a leadership role in bringing such an important advance to cancer patients in the UK, thus allowing treatment at home versus abroad,” said Simon Grinstead, Chief Executive Officer of APS.
Proton beam therapy is the next generation in radiation therapy treating solid tumors. Unlike conventional radiation, proton beam therapy can deliver a highly precise and direct dose of radiation to the tumor, minimizing damage to surrounding healthy tissue and reducing side effects.
APS in conjunction with Valentine Investments Ltd. announced earlier this month that the City of London granted planning permission (zoning approval) to develop the Moorgate property for a proton beam therapy center, a new purpose-built health facility. The development will be on four levels below ground, together with ground and seven upper floors, plus plant areas. The four basement levels will house ProTom’s proton beam therapy equipment, and the upper floors will include ancillary uses such as treatment and consulting rooms, offices, and storage.
About ProTom International, Inc.
Headquartered in Flower Mound, Texas, ProTom is a medical device company focused on increasing the availability and accessibility of proton therapy in order to improve treatment outcomes and quality of life for cancer patients. ProTom’s unique and new generation technology allows facilities to be built on a smaller scale and at a substantially lower capital cost, significantly reducing ongoing operational expenses. For more information, visit www.ProTomInternational.com.
About Advanced Proton Solutions Holdings Limited
Advanced Proton Solutions Holdings Limited, a Jersey CI company, develops and operates cancer treatment centers using the latest technologies. It currently has three projects underway in the United States in partnership with major medical institutions. The London facility is the first of a number of non-US projects in which APS is involved. For more information, visit www.AdvancedProtonSolutions.com.
ProTom International, Inc.
Cheryl Smith, 972-410-3551
csmith@protominternational.com
©
Reuters
* Reuters is not responsible for the content in this press release.
New proton beam therapy center in the City of London to install ProTom’s Radiance 330TM proton therapy system
ProTom International, Inc. (“ProTom”) is proud to announce it has entered into an arrangement with United Kingdom-based Advanced Proton Solutions Holdings Limited (“APS”) to provide its Radiance 330 proton therapy system for the new APS facility that will be built in the City of London.
“Advanced Proton Solutions represents an ideal partner for ProTom’s first international venture. Due to its modular design and smaller footprint, our Radiance 330 system is a great solution for sustainable urban locations such as the City of London,” said Stephen Spotts, CEO of ProTom.
“Proton beam therapy represents an innovation in cancer treatment, and ProTom’s technology will allow the development of the APS purpose-built facility in Moorgate, City of London. APS is proud to take a leadership role in bringing such an important advance to cancer patients in the UK, thus allowing treatment at home versus abroad,” said Simon Grinstead, Chief Executive Officer of APS.
Proton beam therapy is the next generation in radiation therapy treating solid tumors. Unlike conventional radiation, proton beam therapy can deliver a highly precise and direct dose of radiation to the tumor, minimizing damage to surrounding healthy tissue and reducing side effects.
APS in conjunction with Valentine Investments Ltd. announced earlier this month that the City of London granted planning permission (zoning approval) to develop the Moorgate property for a proton beam therapy center, a new purpose-built health facility. The development will be on four levels below ground, together with ground and seven upper floors, plus plant areas. The four basement levels will house ProTom’s proton beam therapy equipment, and the upper floors will include ancillary uses such as treatment and consulting rooms, offices, and storage.
About ProTom International, Inc.
Headquartered in Flower Mound, Texas, ProTom is a medical device company focused on increasing the availability and accessibility of proton therapy in order to improve treatment outcomes and quality of life for cancer patients. ProTom’s unique and new generation technology allows facilities to be built on a smaller scale and at a substantially lower capital cost, significantly reducing ongoing operational expenses. For more information, visit www.ProTomInternational.com.
About Advanced Proton Solutions Holdings Limited
Advanced Proton Solutions Holdings Limited, a Jersey CI company, develops and operates cancer treatment centers using the latest technologies. It currently has three projects underway in the United States in partnership with major medical institutions. The London facility is the first of a number of non-US projects in which APS is involved. For more information, visit www.AdvancedProtonSolutions.com.
ProTom International, Inc.
Cheryl Smith, 972-410-3551
csmith@protominternational.com
©
